Greenlane Holdings, Inc. current report, 24 January 2024

Greenlane Holdings, Inc. — Form 8-K Summary

Reporting period and context: This Form 8-K was filed January 30, 2024, regarding events beginning January 24, 2024. Greenlane Holdings, Inc. is a Delaware company whose Class A common stock trades on Nasdaq under the symbol GNLN.

Material Event and Governance Changes

  • Independent director Gina Collins resigned from the Board and all Board committees effective immediately on January 24, 2024.
  • The filing states that her resignation was not due to any disagreement with the Company regarding operations, policies, practices, management, or the Board.
  • Following the resignation, independent directors no longer constitute a majority of the Board, resulting in noncompliance with Nasdaq Listing Rule 5605(b)(1).
  • The Board’s Audit Committee also no longer has at least three independent directors, resulting in noncompliance with Nasdaq Listing Rule 5605(c)(2)(A).
  • The Company notified Nasdaq on January 29, 2024, and received Nasdaq’s acknowledgment of the noncompliance on January 30, 2024.

Financial Metrics and Liquidity

This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, balance-sheet, or other financial performance metrics.

Compliance Timeline and Outlook

  • The Company has until the earlier of its next annual stockholders meeting or January 24, 2025, to regain compliance.
  • If the next annual meeting occurs before July 22, 2024, the Company must demonstrate compliance by July 22, 2024.
  • Management intends to identify and appoint a replacement director who satisfies applicable Nasdaq independence and committee requirements before the applicable cure period expires.

Risks and Unusual Items

The principal disclosed risk is potential continued noncompliance with Nasdaq’s board and Audit Committee composition requirements. The filing does not state that Nasdaq has initiated delisting proceedings or that the Company’s securities have been suspended. Failure to regain compliance within the applicable cure period could create additional listing-related consequences.

Key Facts for Investors to Verify

  • Whether the Company appointed a qualifying independent director before the applicable Nasdaq deadline.
  • Whether the Board again achieved a majority of independent directors.
  • Whether the Audit Committee was restored to at least three independent directors.
  • Whether Nasdaq granted any additional extension or issued further notices concerning listing compliance.
  • The filing does not provide a clear value for any financial performance metric.